Stockscreener 앱 받기
14.49
3.53%
-0.53
시간 외 거래:
14.49
전일 마감가:
$15.02
열려 있는:
$15.18
하루 거래량:
2.87M
Relative Volume:
2.64
시가총액:
$785.15M
수익:
-
순이익/손실:
$-883.08M
주가수익비율:
-0.0435
EPS:
-333.4782
순현금흐름:
$-150.65M
1주 성능:
+2.84%
1개월 성능:
+2.55%
6개월 성능:
+13.20%
1년 성능:
+238.55%
1일 변동 폭
$14.38
$15.44
1주일 범위
$13.45
$15.44
52주 변동 폭
$4.2898
$65.80
보 바이오파마 Stock (VOR) Company Profile
명칭
Vor Biopharma Inc
전화
617-655-6580
주소
500 BOYLSTON STREET, BOSTON
Compare VOR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
14.49 | 785.15M | 0 | -883.08M | -150.65M | -333.48 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
보 바이오파마 Stock (VOR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-30 | 개시 | Jefferies | Buy |
| 2026-03-19 | 개시 | Wells Fargo | Overweight |
| 2026-01-09 | 개시 | Citigroup | Buy |
| 2025-12-17 | 개시 | TD Cowen | Buy |
| 2025-12-09 | 개시 | JP Morgan | Overweight |
| 2025-11-25 | 재개 | Wedbush | Neutral |
| 2025-10-15 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-09-24 | 업그레이드 | Stifel | Hold → Buy |
| 2025-06-30 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-07-26 | 개시 | Wedbush | Outperform |
| 2022-04-27 | 개시 | Goldman | Neutral |
| 2021-12-17 | 개시 | H.C. Wainwright | Buy |
| 2021-12-03 | 개시 | Robert W. Baird | Outperform |
| 2021-12-02 | 개시 | Oppenheimer | Outperform |
| 2021-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2021-03-25 | 개시 | B. Riley Securities | Buy |
| 2021-03-03 | 개시 | Barclays | Overweight |
| 2021-03-03 | 개시 | Evercore ISI | Outperform |
| 2021-03-02 | 개시 | Goldman | Sell |
| 2021-03-02 | 개시 | Stifel | Buy |
모두보기
보 바이오파마 주식(VOR)의 최신 뉴스
Vor Biopharma Inc (VOR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vor Biopharma Inc (VOR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vor Biopharma Inc (VOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vor Biopharma Inc (VOR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vor Biopharma Inc (VOR) Institutional Confidence - TradingKey
Vor Biopharma Inc (VOR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vor Biopharma Inc (VOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vor Biopharma Inc (VOR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vor Biopharma Inc (VOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vor Biopharma Q1 2026 Earnings: Deep EPS Miss Amid Ongoing R&D Investment; Stock Edges HigherOne-Time Loss Impact - newsline.com
Vor Biopharma (VOR) Stock Analysis Report | Financials & Insights - Benzinga
[Form 4] Vor Biopharma Inc. Insider Trading Activity - Stock Titan
Vor Biopharma (VOR) director receives 53,283 stock options at $14.09 strike - Stock Titan
Vor Biopharma (VOR) grants Alexander Cumbo 56,345 stock options - Stock Titan
Vor Biopharma (NASDAQ: VOR) updates and wins approval for 2021 equity plan - Stock Titan
Vor Biopharma (VOR) Stages 3.12% Rally: Potential Breakout Above $15.26 in Sight?Jelly Roll Trade - newsline.com
symbol__ Stock Quote Price and Forecast - CNN
Vor Bio gains boost from telitacicept IgA nephropathy approval - TipRanks
Vor Bio (VOR) drug telitacicept gains China NMPA nods in IgAN and Sjögren’s - Stock Titan
Vor Bio (VOR) Secures Conditional Approval for Telitacicept in C - GuruFocus
Vor Biopharma Inc. and RemeGen Co., Ltd. Receives NMPA Conditional Approval For Telitacicept For The Treatment Of IgA Nephropathy In China - marketscreener.com
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China - Yahoo Finance
Vor Biopharma (VOR) Slips Over 8% as Biotech Sentiment WeighsThematic ETF Flow - newsline.com
Vor Biopharma (VOR) Declines Over 8% as Biotech Sector Faces Headwinds; Key Support Levels TestedMomentum Factor - newsline.com
Vor Biopharma (VOR) Drops Over 8% as Shares Approach Key SupportMax Pain Level - newsline.com
GREAT POINT PARTNERS LLC's Vor Biopharma Inc(VOR) Holding History - GuruFocus
VOR Stock Chart | VOR BIOPHARMA INC (NASDAQ:VOR) - ChartMill
Vor Biopharma’s Phase 3 Sjögren’s Trial Puts Telitacicept on Investors’ Radar - TipRanks
VOR: Advancing telitacicept in global phase III trials for MG and Sjögren's, targeting major markets - TradingView
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biotech Vor Bio hands 61,050 options, 12,900 RSUs to new staff - Stock Titan
Vor Biopharma (VOR) price target decreased by 10.34% to 37.13 - MSN
Vor Biopharma (VOR) Stock Eases Slightly as Shares Hold Near Key Support ZoneSign of Strength - newsline.com
Autoimmune biotech Vor Bio to share update at 2026 Jefferies conference - Stock Titan
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference - marketscreener.com
Vor Biopharma Surges 5.46% as Buyers Defend Key Support Level (VOR)Undervalued Stocks - newsline.com
VOR Stock Price, Quote & Chart | VOR BIOPHARMA INC (NASDAQ:VOR) - ChartMill
VOR Q1 2026 Earnings: EPS Misses by Substantial Margin Amid Ongoing Pipeline DevelopmentGross Profit Margin - newsline.com
VOR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $31 - GuruFocus
H.C. Wainwright Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Vor Biopharma Price Target Maintained With a $31.00/Share by HC Wainwright & Co. - Moomoo
Vor Biopharma Shares Skyrocket on Global Licensing Deal for Autoimmune Therapy - MSN
Vor Biopharma Inc.Common Stock (NQ: VOR - FinancialContent
Venrock group holds capped 9.99% stake in VOR (VOR) via pre-funded warrants - Stock Titan
Verve Capital amends position; holds 9.3% of VOR (NASDAQ: VOR) - Stock Titan
We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate - Moomoo
We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely - Yahoo Finance
Vor Biopharma: Enrollment on Track for Phase 3 UPSTREAM MG Trial of Telitacicept in Generalized Myasthenia Gravis Patients With Topline Results Anticipated in 1H27 >VOR - Moomoo
VOR Maintained by Wedbush -- Price Target Raised to $18.00 - GuruFocus
Wells Fargo Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Phase 3 IgA kidney drug telitacicept cuts protein loss 55% in China trial - Stock Titan
보 바이오파마 (VOR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):